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Abstract
Background: Enhancer of zeste 2 (EZH2) promotes prostate cancer progression. We
hypothesized that increased EZH2 expression is associated with postradiotherapy
metastatic disease recurrence, and may promote radioresistance.
Methods: EZH2 expression was investigated using immunohistochemistry in
diagnostic prostate biopsies of 113 prostate cancer patients treated with radio-
therapy with curative intent. Associations between EZH2 expression in malignant and
benign tissue in prostate biopsy cores and outcomes were investigated using
univariate and multivariate Cox regression analyses. LNCaP and PC3 cell radio-
sensitivity was investigated using colony formation and γH2AX assays following
UNC1999 chemical probe‐mediated EZH2 inhibition.
Results: While there was no significant association between EZH2 expression and
biochemical recurrence following radiotherapy, univariate analysis revealed that
prostate cancer cytoplasmic and total EZH2 expression were significantly associated
with metastasis development postradiotherapy (P = 0.034 and P = 0.003, respec-
tively). On multivariate analysis, the prostate cancer total EZH2 expression score
remained statistically significant (P = 0.003), while cytoplasmic EZH2 expression did
© 2019 The Authors. The Prostate Published by Wiley Periodicals, Inc.
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not reach statistical significance (P = 0.053). No association was observed between
normal adjacent prostate EZH2 expression and biochemical recurrence or metastasis.
LNCaP and PC3 cell treatment with UNC1999 reduced histone H3 lysine 27 tri‐
methylation levels. Irradiation of LNCaP or PC3 cells with a single 2 Gy fraction with
UNC1999‐mediated EZH2 inhibition resulted in a statistically significant, though
modest, reduction in cell colony number for both cell lines. Increased γH2AX foci
were observed 24 hours after ionizing irradiation in LNCaP cells, but not in PC3,
following UNC1999‐mediated EZH2 inhibition vs controls.
Conclusions: Taken together, these results reveal that high pretreatment EZH2
expression in prostate cancer in diagnostic biopsies is associated with an increased
risk of postradiotherapy metastatic disease recurrence, but EZH2 function may only
at most play a modest role in promoting prostate cancer cell radioresistance.
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1 | INTRODUCTION
An estimated 164 690 new prostate cancer (PCa) cases were
diagnosed in the United States (US) alone in 2018.1 Radical
treatment options for localized PCa include radical surgery and
radical radiotherapy (RT), which have equivalent cure rates at a
median follow‐up of 10 years.2 Almost half of the men with high‐risk
localized PCa currently receive RT with curative intent,3 and while
concomitant androgen deprivation therapy (ADT)4,5 and advances in
external beam RT delivery6,7 have improved treatment, RT does not
cure all patients. In particular, high‐risk localized PCa can recur
following RT, with 5‐year disease‐free survival rates of 78% to 94%
being reported for RT plus ADT in large series.4,8–10
The Polycomb Group protein enhancer of zeste 2 (EZH2)
promotes PCa development11 and is implicated in tumor cell
proliferation, invasiveness, metastasis, and progression to a castra-
tion‐resistant phenotype.12–20 EZH2 functions within the Polycomb
Repressive Complex 2 (PRC2) in concert with histone deacetylases
(HDACs),21,22 and catalyzes a transcriptionally repressive histone H3
lysine 27 tri‐methylation signal.23–26 This results in the recruitment
of PRC1, heterochromatin formation, DNA methylation, and gene
silencing.23,24,26,27 Epigenetic regulators mediate resistance to antic-
ancer therapies such as RT through several mechanisms,28–30 and
HDAC inhibitors can increase radiosensitivity in several cancers31,32
including PCa.33
This study tested the hypothesis that increased EZH2 expression
in baseline diagnostic PCa biopsy clinical samples may be associated
with subsequent post‐RT disease recurrence, and that inhibition of
EZH2 function might increase PCa cell radiosensitivity in vitro. We
report that patients whose PCa tumors expressed high levels of
EZH2 at baseline experienced an increased risk of metastatic disease
relapse following RT. We also observed that in vitro inhibition of
EZH2 function in PCa cells resulted in only a modest increase in
sensitivity to RT treatment. Taken together, these results suggest
that increased EZH2 function in PCa promotes post‐RT metastatic
recurrence through mechanisms above and beyond increased
intrinsic radioresistance alone.
2 | MATERIALS AND METHODS
2.1 | Patient cohort and clinical follow‐up
The study population comprised 113 men with PCa who received
external beam radical RT with curative intent in Oxford between
2000 and 2005 (from a database of approximately 800 such PCa
patients), and from whom pretreatment prostate biopsy slides were
archived and available, and on whom outcome data were ascertained.
Anonymous clinical data were available from medical chart review,
including age at diagnosis, date of RT treatment, prostate‐specific
antigen (PSA) at diagnosis and during follow‐up, initial standard‐of‐
care contemporary staging imaging where performed (usually
comprising isotope bone scan or computed tomography (CT) scan if
high‐risk disease or PSA greater than 20 ng/ml at diagnosis), clinical
tumor (cT) stage, biopsy Gleason grade group, and clinical follow‐up
data for biochemical recurrence (BCR) and/or distant metastasis.
Patients were reviewed in the clinic at least once every 6 months
after RT, for a minimum of 3 years. External beam RT was 3D
conformal and CT planned, and typically a 55Gy dose was delivered
to the planned target volume in twenty fractions over 4 weeks with
neoadjuvant and concurrent ADT as previously described.34,35
Assuming α/β ratio for PCa of 1.8 Gy,36 this dose/fractionation
schedule is equivalent to 65.9 Gy in 2 Gy fractions. RT was
administered to all other patients in fractions of 2 Gy. Using follow‐
up data including serial PSA monitoring, isotope bone scans, CT
scans, magnetic resonance imaging (MRI) and positron emission
tomography (PET)/CT scans, patients were assigned to one of three
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mutually exclusive groups: long‐term remission, BCR, or radiologi-
cally confirmed distant metastatic relapse. BCR was defined using the
ASTRO‐Phoenix Consensus criteria37 as a PSA rise greater than 2 ng/
ml above the post‐RT nadir, without evidence of metastatic disease,
and if this occurred patients would usually be commenced on ADT,
unless contra‐indicated due to competing comorbidity or frailty.
Metastatic PCa was defined as bony, visceral, or lymph‐node
metastases on follow‐up imaging (isotope bone scan, or MRI, or
PET/CT scan), or inferred by a PSA rise to greater than 100 ng/ml.
The study had institutional ethical committee approval (ORB ethics
09/H0606/5 + 5), and appropriate checks for patient consent for
anonymous use of tissue for research were undertaken.
2.2 | Immunohistochemistry
Archival diagnostic formalin‐fixed paraffin‐embedded (FFPE) prostate
biopsy samples were selected for this study as described pre-
viously.34,35 Sections were deparaffinized and rehydrated in the
standard manner, endogenous peroxidase activity was inactivated
using 3% H2O2 in methanol, blocked with 5% normal goat serum and
incubated with a previously validated anti‐EZH2 primary antibody
(anti‐EZH2, clone AE25, cat. no. MABE362, 1:1000; Merck Millipore,
Watford, UK)38 at 4°C overnight. Following the addition of a
biotinylated secondary antibody, an avidin/biotin‐based peroxidase
solution was added, followed by 3,3′‐diaminobenzidine solution
hematoxylin counterstaining. Sections were dehydrated and mounted
as standard. Stained PCa biopsy samples were scored by a consultant
uropathologist blinded to patient‐ and tumor characteristics, and a
malignant epithelium EZH2 expression intensity score was assigned
ranging from 0 (no expression) to 3 (maximal expression), which was
multiplied by the percentage of stained cells, to yield a total PCa EZH2
expression score (range, 0‐300) for each of “nuclear” and “cytoplasmic”
EZH2. A PCa “total” EZH2 expression score was calculated as the sum
of nuclear plus cytoplasmic staining (range, 0‐600). Where “normal
adjacent benign prostate” tissue was available within the prostate
biopsy samples, a benign “nuclear,” “cytoplasmic,” and “total” EZH2
expression score was similarly obtained.
2.3 | Cell culture and UNC1999 treatment
LNCaP and PC3 human PCa cell lines were purchased from American
Type Culture Collection (ATCC, Manassas, VA) and maintained in
Roswell Park Memorial Institute (RPMI)‐1640 (Gibco, Fisher Scien-
tific UK Ltd, Loughborough, UK) supplemented with 10% fetal bovine
serum (FBS) in 5% CO2 at 37°C as previously described.
12,13 All cell
lines were regularly tested for the absence of Mycoplasma and
continuously cultured for no more than 3 months. These cells were
chosen as they are widely used in in vitro PCa research, and can be
maintained and grown at the necessary cell density required for
clonogenic assays. Cells were treated with the EZH2 chemical probe
inhibitor UNC1999 (0.1, 0.5, 1.0 μM for LNCaP, and 2.0, 4.0, 6.0 μM
for PC3) or an equivalent percentage of dimethyl sulfoxide (DMSO)
as a solvent‐treated control for the indicated time‐courses.
2.4 | Immunoblotting
Protein lysates were prepared using radioimmunoprecipitation
assay (RIPA) lysis buffer (0.1% sodium dodecyl sulfate, 1% NP‐40,
1 mM ethylenediaminetetraacetic acid (EDTA), 50 mM Tris PH 7.5,
150 mM NaCl, 0.25% deoxycholate) with protease and phospha-
tase inhibitors (Roche, Welwyn Garden City, UK). Protein
concentration was determined using the Pierce bicinchoninic
acid assay (BCA) Protein Assay Kit (ThermoFisher Scientific,
Hemel Hempstead, UK). Following sodium dodecyl sulfate poly-
acrylamide gel electrophoresis electrophoresis and subsequent
immunoblotting, bound anti‐EZH2 antibody (1:1000), anti‐histone
H3 tri‐methyl K27 (1:1000), anti‐β‐tubulin (1:1000), was detected
by developing film from Western blot analysis substrate (Promega,
Southampton, UK).
2.5 | Antibodies
The following antibodies were used in this study: anti‐Histone H3 tri‐
methyl K27 (ab192985; Abcam, Cambridge, UK), anti‐EZH2 (clone
AE25, cat. no. MABE362; Merck Millipore, Watford, UK) and
anti‐β‐tubulin (T4026; Sigma‐Aldrich, Gillingham, UK) for immuno-
blotting; anti‐EZH2 for immunohistochemistry (anti‐EZH2, clone
AE25, cat. no. MABE362, 1:1000; Merck Millipore, Watford, UK)38;
anti‐γH2AX for immunofluorescence (05‐636‐AF555, 1:500; Merck
Millipore, Watford, UK).
2.6 | Colony formation assays and γH2AX
immunofluorescence
LNCaP and PC3 cells were treated with UNC1999 inhibitor or
DMSO as a negative control for 96 hours, and then lifted, diluted
and plated into six‐well plates in triplicate to perform a colony‐
formation assay (CFA). Approximately 500 PC3 cells and 6000
LNCaP cells were plated ahead of irradiation in medium containing
DMSO control or UNC1999 at different doses. Cells were left for
24 hours at 37°C (5% CO2) to settle and adhere, and treatment
plates were then irradiated at 2, 4, and 6 Gy using a Caesium‐137
irradiator, Gamma Service: GSR D1; dose rate 1.938 Gy/min. At
24 hours postirradiation, cells were changed to medium without
UNC1999. Colonies were grown for 10 to 14 days postirradiation
and then stained with crystal violet, and colonies were then
counted using a GelCount colony counter (Oxford Optronix,
Abingdon, UK). Effects of UNC1999 treatment on the number of
surviving colonies at 0, 2, 4, and 6 Gy were compared against
DMSO‐treated control cells using a paired t test. For γH2AX foci
analysis, UNC1999 and DMSO control‐treated cells were irra-
diated as described above, and then fixed at different time points
using 4% paraformaldehyde, and permeabilized by fresh 0.1%
Triton X‐100 in 4% fetal calf serum‐containing solution. Cells were
probed with an anti‐γH2AX antibody, and foci were imaged using a
Zeiss LSM 710 confocal microscope and quantified using ImageJ
software (NIH Image, NIH, Bethesda, MD).
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2.7 | Statistical analysis
We sought to assess whether EZH2 expression levels, as determined
by immunohistochemistry on pre‐RT prostate biopsy samples, could
predict BCR or distant metastasis after RT when added to standard
predictors. Firstly, we assessed the univariate association between
EZH2 expression levels (nuclear, cytoplasmic, and total [nuclear plus
cytoplasmic]) per 100‐unit change, and the outcome (BCR and
metastasis respectively), using Cox regression. We then studied the
multivariate association, using Cox regression, between EZH2
expression level and the outcomes, adjusting for PSA, cT stage, and
biopsy Gleason grade group. Due to the limited number (n = 17) of
patients with image‐confirmed metastatic disease during follow‐up it
was not feasible to include these covariates in a single model.
Therefore, a risk score was created using PSA (cubic splines were
used to account for nonlinearity), cT stage (cT1 vs cT2 vs cT3/4), and
biopsy Gleason grade group (1 vs 2 vs ≥ 3) to predict BCR after
external beam radical RT treatment. The risk score was then utilized
for model adjustment. For models where the EZH2 expression score
was significantly associated with the outcome on multivariate
analysis, the improvement in discrimination (Harrell's c‐index) was
reported and corrected for optimism (to attenuate the discrimination
estimate slightly, to better estimate the true discrimination) using
bootstrap methods.39 BCR free‐ and metastasis‐free survival was
calculated using Kaplan‐Meier analysis, and patients who did not
recur were censored at the date of last clinical follow‐up. All
statistical analyses of the clinical cohort and EZH2 expression were
performed using Stata 15.0 (StataCorp, College Station, TX).
All statistical tests of in vitro experiment data were performed as
two‐tailed t tests and differences were considered significant at a
P < 0.05. All in vitro colony formation assay data are representative
of three independent experiments, each being performed in
triplicate, and are presented as the mean ± standard error of the
mean (SEM) from these multiple repeat experiments.
3 | RESULTS
3.1 | Increased EZH2 expression is associated with
prostate cancer metastatic disease recurrence
following external beam radical radiotherapy
One hundred thirteen patients with available archival FFPE tissue
and clinical follow‐up data were identified from a database of
approximately eight hundred PCa patients who received external
beam RT with curative intent at our institution between 2000 and
2005. Patient and tumor characteristics (for whom no data were
missing for multivariate analysis) are described in Table 1. The
majority of patients had biopsy Gleason grade group 2 to 3, and
cT2‐3, PCa. The median pretreatment PSA value was 13.0 ng/mL
(interquartile range [IQR], 7.6‐20.4 ng/mL). Nuclear, cytoplasmic, and
total (nuclear + cytoplasmic) EZH2 expression scores for both PCa
tissue (N = 113) and “benign normal adjacent prostate tissue” were
available in the biopsy cohort (N = 95 of 113 cases), are shown in
Table 2. Over a median follow‐up of 7.9 years (IQR, 6.8‐8.4 years) for
TABLE 1 Patient cohort characteristics
N= 113
Median PSA value, ng/mL 13.0 (IQR, 7.6‐20.4)
Gleason grade group, N (%)
1 26 (23)
2 30 (27)
3 44 (39)
4 7 (6.2)
5 6 (5.3)
Clinical T‐stage, N (%)
1 30 (27)
2 41 (36)
3 41 (36)
4 1 (0.9)
Abbreviations: IQR, interquartile range; PSA, prostate‐specific antigen.
Baseline patient and tumor characteristics for 113 patients undergoing external beam radiotherapy with curative intent for prostate cancer are outlined.
TABLE 2 Prostate biopsy EZH2 scores
Prostate cancer (N = 113)
Median “nuclear” EZH2 expression score 40 (IQR, 15‐120)
Median “cytoplasmic” EZH2 expression score 140 (IQR, 80‐210)
Median “total” (nuclear + cytoplasmic) EZH2
expression score
230 (IQR, 160‐300)
“Normal adjacent benign prostate tissue” (N = 95 of 113)
Median “nuclear” EZH2 expression score 40 (IQR, 15‐120)
Median “cytoplasmic” EZH2 expression score 0 (IQR, 0‐40)
Median “total” (nuclear + cytoplasmic) EZH2
expression score
80 (IQR, 30‐140)
Baseline EZH2 scores for the malignant areas of prostate biopsies from
samples from N = 113 patients, and for the “normal adjacent benign
prostate tissue” where available (in N = 95 of 113 patients), are shown.
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the entire cohort, 63 of 113 (56%) patients developed any disease
recurrence (defined as BCR or metastatic recurrence). 18 of 113
(16%) patients developed definite metastatic disease recurrence, as
defined by bone or soft tissue lesions on radionuclide or CT imaging,
or a PSA rise to greater than 100 ng/mL.
The median follow‐up time for patients who did not develop BCR
was 7.8 years (IQR, 6.7‐8.3 years). The 5‐ and 10‐year BCR‐free
survival was 72% (95% confidence interval [CI], 63%‐79%) and 22%
(95% CI, 6%‐44%), respectively (Figure 1A). No significant association
between PCa tissue EZH2 staining levels (nuclear, cytoplasmic, or
total) and BCR was observed on either univariate or multivariate
analysis (Table 3A).
The median follow‐up time for patients who did not develop
metastasis was 8.1 years (IQR, 7.4‐8.5 years). The 5‐ and 10‐year
metastasis‐free survival was 94% (95% CI, 87%‐97%) and 80% (95%
CI, 68%‐88%), respectively (Figure 1B). On univariate analysis, PCa
tissue cytoplasmic EZH2 expression score, and total (nuclear +
cytoplasmic) EZH2 expression score were significantly associated
with the development of distant metastasis (P = 0.034 and P = 0.003,
respectively (Table 3B). Figure 2 demonstrates that cytoplasmic
EZH2 expression was higher in baseline PCa tissue biopsy samples
from patients with subsequent metastatic disease recurrence. On
multivariate analysis, the PCa tissue total EZH2 expression score
remained significantly associated with metastatic disease recurrence
(P = 0.003), while the PCa tissue EZH2 cytoplasmic expression score
fell marginally short of the conventional level of statistical
significance (P = 0.053).
The discrimination of the base model (utilizing PSA, Gleason
grade group, and cT stage at baseline diagnostic prostate biopsy) for
predicting the development of distant metastasis following external
beam radical RT was 0.594. After the inclusion of PCa tissue
cytoplasmic and total EZH2 expression scores, the optimism‐
corrected discrimination estimates for PCa tissue cytoplasmic and
total EZH2 expression were 0.676 and 0.723, respectively, repre-
senting potentially important improvements in the model's ability to
predict the development of posttreatment metastasis following
external beam radical RT when PCa tissue EZH2 expression
quantification from initial diagnostic biopsies is included.
On univariate and multivariate analysis, “normal adjacent benign
prostate” tissue EZH2 expression scores were not significantly
associated with the development of either post‐RT BCR or distant
metastasis (Tables 3C and 3D).
3.2 | Investigating the effects of
UNC1999‐mediated inhibition of EZH2 function on
radiosensitivity of LNCaP prostate cancer cells
LNCaP and PC3 PCa cells were treated with various concentrations
of the chemical probe UNC1999, which inhibits EZH2 function. As
demonstrated by immunoblotting of whole cell lysate preparations,
steady‐state H3K27Me3 levels were reduced in both LNCaP and
PC3 cells following 4 days of treatment with UNC1999 (Figure 3A),
confirming that UNC1999 inhibits the histone methyl‐transferase
function of EZH2. Given that inhibition of EZH2 inhibits cellular
proliferation12 which itself would preclude colony formation in vitro,
the lowest doses of UNC1999 with demonstrable inhibition of EZH2‐
mediated H3K27Me3 (0.5 µM for LNCaP, and 4.0 μM for PC3) were
taken forward for radiosensitivity experiments.
LNCaP and PC3 human PCa cells were treated with ionizing
irradiation in the presence of UNC1999, to investigate any potential
radiosensitizing effects of EZH2 functional inhibition. Treatment of
LNCaP cells with 2 Gy ionizing irradiation in the transient (ie, first
24 hours post‐RT) presence of 0.5 μM UNC1999‐mediated EZH2
inhibition resulted in a modest but statistically significant reduced
number of surviving LNCaP cell colonies (*P < 0.05) (Figure 3B).
Irradiation of PC3 cells with 2 Gy ionizing irradiation in the transient
presence of 4.0 μM UNC1999 also resulted in a modest but
statistically significant reduced number of surviving cell colonies
(*P < 0.05) (Figure 3B).
γH2AX foci were quantified using immunofluorescence in LNCaP and
PC3 cells at 2 and 24hours following 2Gy ionizing irradiation ±
UNC1999‐mediated EZH2 inhibition. A significantly higher number of
F IGURE 1 Posttreatment tumor recurrence in the clinical cohort.
Biochemical recurrence‐free survival (A) and metastasis‐free survival
(B) for the cohort following external beam radical radiotherapy with
curative intent
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γH2AX foci was seen following 0.5 μM UNC1999‐mediated EZH2
inhibition vs DMSO control treated cells at 24 hours postirradiation in
LNCaP cells (*P<0.05) (Figure 4). However, this effect on γH2AX foci
formation was not observed in PC3 cells treated with 4.0μMUNC‐1999.
4 | DISCUSSION
EZH2 has been implicated in PCa development and progression,11–20
but to date, this knowledge has not yielded clinical benefit for patients.
While delivery of external beam RT as a curative treatment option for
men with PCa has improved, many patients develop disease
recurrence despite concurrent ADT. There is an unmet clinical need
to identify druggable targets to increase tumor radiosensitivity,40,41
and to identify markers of RT treatment failure. We provide evidence
that EZH2 overexpression in pretreatment PCa biopsies is associated
with subsequent metastatic PCa recurrence following radical RT.
EZH2 is overexpressed in castration‐resistant PCa, and RT can
reduce EZH2 expression in PCa cells.42 Moreover, small molecule
inhibitors of EZH2 can induce cell death in vitro and in vivo in
advanced PCa.42 However, studies specifically investigating links
between EZH2 expression and PCa recurrence following RT, or the
potential for inhibitors of EZH2 to radiosensitize PCa cells, are lacking.
Studies in other malignancies suggest that inhibiting EZH2 may
enhance RT‐induced inhibition of cancer growth.43,44 Non‐small–cell
lung cancer studies suggest the efficiency of combined anti‐EZH2 and
RT treatment to inhibit cancer cell proliferation differs in various
cancer cell lines based on EZH2 expression levels.43 We previously
demonstrated that LNCaP and PC3 cells express EZH2, and are
sensitive to antiproliferative effects of small interfering RNA (siRNA)‐
mediated EZH2 inhibition.12 While our experiments suggest the
radiosensitivity of both LNCaP and PC3 cells can be increased
through UNC1999‐mediated inhibition of EZH2 function, this is only a
relatively modest effect, suggesting other biological mechanisms may
TABLE 3 Univariate and multivariate analysis of EZH2 expression in the clinical cohort. Univariate and multivariate analyses predicting
biochemical recurrence (A) and distant metastasis (B) after external beam radical radiotherapy, based on analysis of the malignant tissue in
diagnostic prostate cancer samples. Univariate and multivariate analyses predicting biochemical recurrence (C) and distant metastasis (D) after
external beam radical radiotherapy, based on analysis of the “normal adjacent benign prostate tissue” in diagnostic prostate cancer samples
were available
Univariate Multivariatea
Prostate cancer EZH2 expression HR 95% CI P value HR 95% CI P value
A
Nuclear 0.97 0.71‐1.31 0.8 1.07 0.78‐1.45 0.7
Cytoplasmic 1.29 0.98‐1.70 0.069 1.17 0.87‐1.56 0.3
Total 1.24 0.95‐1.61 0.12 1.21 0.92‐1.60 0.2
Univariate Multivariatea
Prostate cancer EZH2 expression HR 95% CI P value HR 95% CI P value
B
Nuclear 1.30 0.79‐2.13 0.3 1.37 0.83‐2.25 0.2
Cytoplasmic 1.77 1.04‐2.98 0.034 1.70 0.99‐2.92 0.053
Total 2.21 1.32‐3.71 0.003 2.29 1.32‐3.99 0.003
Univariate Multivariatea
“Normal adjacent prostate” EZH2
expression HR 95% CI P value HR 95% CI P value
C
Nuclear 0.71 0.45‐1.12 0.14 0.78 0.49‐1.24 0.3
Cytoplasmic 1.32 0.75‐2.32 0.3 1.21 0.70‐2.12 0.5
Total 0.85 0.57‐1.26 0.4 0.90 0.60‐1.34 0.6
Univariate Multivariatea
“Normal adjacent prostate” EZH2
expression HR 95% CI P value HR 95% CI P value
D
Nuclear 0.68 0.27‐1.70 0.4 0.74 0.29‐1.89 0.5
Cytoplasmic 1.01 0.30‐3.40 1.0 0.96 0.29‐3.22 0.9
Total 0.74 0.34‐1.63 0.5 0.78 0.35‐1.74 0.5
Abbreviations: CI, confidence interval; EZH2, enhancer of zeste 2; HR, hazard ratio; PSA, prostate‐specific antigen.
Values in bold represent P<0.05.
Hazard ratios are shown for a 100‐unit change in EZH
aMultivariate models adjusted for: PSA, biopsy Gleason score, and clinical T‐stage.
1084 | WU ET AL.
F IGURE 2 Enhancer of Zeste 2 (EZH2) expression analysis in the prostate cancer cohort treated with radical radiotherapy. Increased EZH2
expression was observed in baseline prostate cancer biopsy samples from individuals with subsequent metastatic progression following radical
radiotherapy. PSA, prostate‐specific antigen [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 3 Inhibition of EZH2 function in prostate cancer cells reduced H3K27Me3 levels but only resulted in a modest increase in cellular
radio‐sensitivity. H3K27Me3 levels were reduced in LNCaP and PC3 cells following 4 days of treatment with the EZH2‐specific chemical probe
UNC1999 (A). 2 Gy irradiation of LNCaP cells in the transient (first 24 hours post radiotherapy) presence of 0.5 μM UNC1999‐mediated EZH2
inhibition resulted in significantly fewer surviving cell colonies (*P < 0.05), and 2 Gy irradiation of PC3 cells in the transient presence of 4.0 μM
UNC1999 resulted in a significant reduction in surviving cell colonies (*P < 0.05) (B). This effect was only observed with 2 Gy irradiation. Data
shown are means ± SEM of three independent experiments each performed in triplicate. DMSO, dimethyl sulfoxide; EZH2, enhancer of zeste 2
[Color figure can be viewed at wileyonlinelibrary.com]
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F IGURE 4 Inhibition of EZH2 function increased γH2AX foci formation in LNCaP, but not PC3, prostate cancer cells following irradiation.
γH2AX foci were quantified using immunofluorescence in LNCaP and PC3 cells at 2 and 24 hours following 2 Gy radiotherapy ± UNC1999‐
mediated EZH2 inhibition (A). A significantly higher number of γH2AX foci was seen following 0.5 μM UNC1999‐mediated EZH2 inhibition vs
DMSO control treated cells at 24 hours postradiotherapy in LNCaP cells (*P < 0.05), but this effect was not observed in PC3 cells treated with
4.0 μM UNC‐1999 (B). Data shown are the representative results of one of two independent experiments and shown as mean ± SEM of γH2AX
foci quantified for a minimum of 30 cells in each well. DAPI, 4′,6‐diamidino‐2‐phenylindole; EZH2, enhancer of zeste 2. Abbreviations: DMSO,
dimethylsulfoxide; hr, hours; IR, ionizing radiation [Color figure can be viewed at wileyonlinelibrary.com]
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be more significant drivers of metastatic PCa progression post‐RT.
Indeed, the effect of combined EZH2 inhibition and RT on γH2AX foci
formation was only observed in LNCaP cells treated with 0.5 μMUNC‐
1999, and not in PC3 cells treated with 4.0 μM UNC‐1999, suggesting
a potential difference in the sensitivity of these cell lines to DNA
double‐strand breaks induced by the combined treatment. The p53
status of these two cell lines (PC3 being p53‐null, and LNCaP
containing wild‐type p53) might also contribute to the different radio‐
sensitivities observed in our experiments, given the important roles of
p53 in double‐strand break response and DNA repair.45 While further
experiments would be required to test this hypothesis, the available
evidence suggests that any radiosensitizing effect of EZH2 inhibition in
the PCa cell lines tested is modest.
While it is acknowledged that UNC1999 is a selective inhibitor of
both EZH2 and EZH1,46 we observed the expected reduction in
H3K27Me3 levels following treatment of PCa cells with UNC1999.
Additional research is necessary to further understand any potential
differential oncogenic properties of EZH1 vs EZH2.
While studies investigating potential correlations between base-
line EZH2 expression in human cancer samples, and subsequent
response to RT, are generally lacking, EZH2 expression correlates with
locoregional recurrence in inflammatory breast cancer patients who
received RT.47 Overexpression of Bmi‐1, a Polycomb Group protein
with similar function to EZH2, elicits radioprotective effects through
epigenetic effects that counteract the genotoxic insults of RT.48 The
available in vitro and in vivo evidence, together with our observation
that EZH2 expression is associated with metastatic PCa recurrence
following RT and only promotes modest radioresistance, support the
hypothesis that EZH2 function promotes metastatic recurrence post‐
RT, primarily through mechanisms other than increased radioresis-
tance. It remains unknown which of several other downstream
functions of EZH2 might primarily account for mechanisms whereby
EZH2 promotes metastatic PCa recurrence following RT, however one
possibility is that this effect is mediated by increased prostate cancer
cellular motility and invasiveness, as this has been demonstrated to be
directly promoted by cytoplasmic EZH2 in vitro.12,49–51 It may be
hypothesized that increased cytoplasmic EZH2 function, rather than
nuclear function, might promote enhanced PCa cell motility and
invasiveness, thereby increasing the risk of developing micrometas-
tases, resulting in enhanced post‐RT disease recurrence. Moreover, if
cytoplasmic EZH2 is the main contributor towards the total EZH2
score (the sum of nuclear and cytoplasmic EZH2), then this may
explain the observation that cytoplasmic and total EZH2 are
associated with metastatic recurrence. It may be the case that the
transcriptional repressor nuclear function of EZH2 is not a mechanism
underpinning radioresistance, whereas the enhanced cytoplasmic
function of EZH2 may promote cellular micrometastasis, leading to
post‐RT disease recurrence. Intriguingly, experiments using estab-
lished radiation‐resistant PCa cell lines demonstrate that they have
with higher concomitant cellular motility than parental radiosensitive
cell lines.52 Further research is necessary to identify the molecular
mechanisms underpinning the observed link between cytoplasmic
EZH2 expression and post‐RT metastatic recurrence.
Our observation that high levels of EZH2 expression in PCa may
promote post‐RT metastatic recurrence has the potential for clinical
utility in two main areas. Firstly, given that EZH2 inhibitors have
been developed for cancer therapy,53 our in vitro data suggest that
combining external beam RT and EZH2 inhibitors to treat PCa
patients may not result in clinical benefit in terms of radiosensitiza-
tion per se. However, there is secondly the possibility that patients
with high EZH2 expression in baseline samples may benefit from
EZH2 inhibition to reduce the risk of metastatic progression. This
possibility requires further investigation in larger scale prospective
studies.
While the 10‐year BCR‐free survival was low at 22% for patients
within this cohort, this is comparable with reported rates of 30% for
high‐risk disease following external beam RT,54,55 and it is possible
that BCR at such a mature length of follow‐up does not equate to
true disease recurrence. While it is a strength of our study that the
cohort was mature with a median follow‐up of 7.9 (IQR, 6.8‐8.4)
years, we acknowledge that these were not consecutive patients
from our institution due to inherent constraints acquiring archival
tissue with retrospective follow‐up. Indeed, our cohort size of 113
patients is modest, though this has been sufficient to identify other
potential mediators of radioresistance.34,35 Data on the larger cohort
from which these patients originated was unfortunately not available.
It would be helpful to validate our findings in similar cohorts from
independent institutions.
Patients developing metastatic PCa recurrence following external
beam RT may include those with occult micrometastases at the time
of irradiation, along with others with local disease recurrence within
the radiation field due to radioresistant PCa. Thirty percent of post‐
RT BCR is estimated to be due to local recurrence indicative of
clinical radioresistance.56 A weakness of our study is that it is difficult
to differentiate between patients who may have had micrometas-
tases at baseline, and those who may initially have developed local
recurrence with a subsequent metastatic phenotype, because post‐
RT imaging was generally not performed until BCR occurred, and not
all patients in the cohort received re‐staging imaging. A contempor-
ary cohort may receive PSMA‐PET/CT57 to accurately evaluate local
vs metastatic disease recurrence post‐RT, but as this is only a recent
clinical development such a cohort with accurate recurrence
classifications would lack long‐term follow‐up. It will be valuable
for future studies to investigate whether EZH2 expression in pre‐RT
samples predicts post‐RT disease recurrence in cohorts with accurate
post‐BCR stage classifications based on molecular imaging.
5 | CONCLUSIONS
In conclusion, patients with a high level of EZH2 expression in the
baseline diagnostic PCa biopsy specimens had an increased risk of
metastatic disease recurrence following external beam RT with
curative intent. Chemical probe‐mediated inhibition of EZH2 func-
tion only results in a modest increase in radiosensitivity of PCa cells
in vitro. Taken together this suggests that EZH2 function promotes
WU ET AL. | 1087
post‐RT metastatic disease recurrence in PCa patients, and this is
likely to be through mechanisms above and beyond any potential
increased radio‐resistance mediated by EZH2 function.
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